Attruby™(acoramidis):

A New Option for Today’s Patients With ATTR-CM

Tuesday, January 14, 2025

8:30 – 9:30 PM ET

Presented by:

First Name*

Last Name*

Email Address*

Degree*

NPI*

State License #*

State Licensed*

Institution Name*

Business Address

City*

State*

Postal Code*

Phone Number

*I agree and consent to receive emails and phone calls related to the administration of this webinar at the email address and phone number I have provided (including cell phone numbers I provided). By checking this box and clicking "submit", I affirm that I am 18 years of age or older, I agree to the above statement, and confirm that I have read and understood the BridgeBio Privacy Policy.

To help combat spam please answer the following question to continue:

1+1

*Required field.

INDICATION

Attruby™ (acoramidis) is indicated for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions

Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation.

Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

Laboratory Tests

Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m² was observed in the adults with ATTR-CM treated with Attruby versus placebo, respectively, at Day 28 and then stabilized. These changes were reversible after treatment discontinuation.

Use in Specific Populations

Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy. There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.

Please see full Prescribing Information for Attruby at Attruby.com/PI.

3160 Porter Drive, Suite 250, Palo Alto, CA 94304

Attruby is a trademark and the BridgeBio, Inc. corporate logo is a registered trademark of BridgeBio, Inc.
MAT–US-453 V2 12/2024